Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

CORRECTION - Ossur Hf : Transactions in relation to share buyback program

Ossur Hf
Posted on: 21 Aug 17
This is a correction of the announcement from 16:00 21.08.2017 CEST, NO: 61/2017. Reason for the correction: Header incorrect, other information in the announcement is correct. Previous Header: Share buyback program completed Correct Header: Transactions in relation to share buyback program   

Announcement from Össur  hf. No. 62/2017

Reykjavík, 21 August 2017

On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. 

The purpose of the share buyback program was to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program would end no later than 31 July 1018. The Company could purchase up to 5,000,000 shares under the program, corresponding to 1.1% of the current share capital. The total consideration for shares purchased under the program should not exceed USD 10 million.

The following transactions were made under the program in week 1, the period 14 August 2017 - 18 August 2017:

DateNo. of sharesAvg. purchase price DKKTransaction Value DKK
14 August 2017---
15 August 201712,22429.35358,717
16 August 20174,39029.74130,541
17 August 20171,71229.7450,920
18 August 20177,06329.62209,206
Total    25,38929.52749,384

Össur acquired 25,389 shares under the program at the average price of DKK 29.52. Following the above transactions Össur's holding of own shares is 8,286,747 corresponding to 1.90% of the Company's total share capital.

The share buyback program was carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission delegated regulation No. 2016/1052.                                                                                                                                                                

Contact persons:

Jón Sigurðsson, President & CEO                                           Tel: +354 515 1300

Sveinn Sölvason, CFO                                                           Tel: +354 515 1300

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail please register at the following web-site:

About Össur   Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports and prosthetic limbs. A recognized "Technology Pioneer", Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the  market.  Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions.  Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide.

Forward-Looking Statement  This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Share buy back transactions 15.08 - 18.08. 2017

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ossur Hf via GlobeNewswire

Last updated on: 22/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.